<DOC>
	<DOCNO>NCT02967939</DOCNO>
	<brief_summary>A study demonstrate non-inferiority DA-2802 compare ㅍViread® chronic hepatitis B patient</brief_summary>
	<brief_title>Efficacy Safety DA-2802 Chronic Hepatitis B Patients</brief_title>
	<detailed_description>1 . DA-2802 319mg Group : Administration DA-2802 319mg tablet qd placebo tablet match Viread® 300mg 0-48 week . 2 . Viread® 300mg Group : Administration Viread® 300mg tablet qd placebo tablet match DA-2802 319mg 0-48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Patients chronic hepatitis B age 18 year old Subjects evidence demonstrate history chronic hepatitis B least six month time screen visit Subjects HBsAg positive test screen visit Subjects receive hepatitis B treatment , include interferon pegylated interferon , within 24 week start screen test Subjects ALT 80 unit 10 time low normal upper limit time screen Subjects infect hepatitis C , hepatitis D human immunodeficiency virus Subjects creatinine clearance le 50 ml/min screen visit At time screen visit , alphafetoprotein level high 50 ng/ml related image test show hepatocellular carcinoma Subjects decompensated liver disease meet follow criterion : 1 . Total bilirubin level great 2.5 mg/dl 2 . Prothrombin time least 3 second longer normal upper limit 3 . Serum albumin value le 30 g/l 4 . Subjects history ascites , jaundice , bleed varicose vein , hepatic encephalopathy , sign liver failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>